Breaking New Ground

Improving outcomes for people with cancer by translating novel scientific insights into first-in-class immunotherapies

Resilient to Our Core

With grit, expertise and passion, our scientists are enabling transformational shifts in cancer treatment

Learn more about our science

We’re in this Together

We believe that through dedication and with teams that transcend corporate walls, we can transform patient lives

meet our leadership team

Recent News

November 7, 2025
Tizona Therapeutics Presents Clinical Translational Evidence of Dual Innate and Adaptive Immune Activation with TTX-080, a First-in-Class HLA-G Antagonist, in Patients with Advanced Solid Tumors at SITC 2025

October 31, 2024
Tizona Therapeutics Announces Expansion of Phase 1b Clinical Trial to Evaluate TTX-080 in Combination with EGFR Inhibitor Cetuximab and Chemotherapy in Advanced Colorectal Cancer

May 15, 2024
Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head and Neck Squamous Cell Carcinoma at ASCO 2024

View More News

• Home
• About
  • Our Vision
  • Leadership
  • Board of Directors
  • Scientific Advisors
  • Investors
  • IRS Form 8937
• Our Science
  • Pipeline
  • Key Programs
  • Publications
• News
  • Press Releases
• Team Tizona
  • Our Values
  • Culture and Benefits
  • Job Opportunities
• Contact

© 2026 Tizona Therapeutics, Inc. All rights reserved.Website Design: Hane Chow, Inc.